Diabetic nephropathy therapies

Abstract

The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.

1 . A method for reducing creatinine clearance in a subject having or at risk for having diabetes or early stage diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       2 . A method for reducing glomerular hyperfiltration in a subject having or at risk for having diabetes or early stage diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       3 . A method for reducing glomerular hyperperfusion in a subject having or at risk for having diabetes or early stage diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       4 . A method for reducing urinary albumin excretion in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       5 . A method for reducing or preventing kidney weight gain in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       6 . A method for normalizing glomerular filtration rate in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       7 . A method for reducing glomerular hypertrophy in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       8 . A method for reducing proteinuria in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       9 . A method for reducing albuminuria in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       10 . A method for reducing microalbuminuria in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       11 . A method for reducing macroalbuminuria in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       12 . A method for reducing BUN levels in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       13 . A method for reducing inulin clearance in a subject having or at risk for having diabetes or diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       14 . A method for preventing, reducing the risk of, or delaying the onset of diabetic complications in a subject at risk for developing such complications, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       15 . A method for treating incipient diabetic nephropathy in a subject having or at risk for having incipient diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       16 . A method for treating incipient diabetic nephropathy in a subject having or at risk for having early stage diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       17 . A method for treating overt diabetic nephropathy in a subject having or at risk for having overt diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       18 . A method for treating diabetic nephropathy in a subject having or at risk for having diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF in combination with an inhibiting amount of an angiotensin converting enzyme inhibitor.  
   
   
       19 . A method for treating diabetic nephropathy in a subject having or at risk for having diabetic nephropathy, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF in combination with an inhibiting amount of an angiotensin receptor blocker.  
   
   
       20 . A method for treating or preventing early stage aspects of a progressive disease in a subject having or at risk for having such a disease, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       21 . A method of treating progressive renal failure in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent that inhibits CTGF.  
   
   
       22 . A method for improving kidney function in a subject having or at risk for having impaired kidney function, the method comprising administering to the subject a therapeutically effective amount of a an agent that inhibits CTGF.